Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Sun Pharma Buys Additional Stake In Taro, Will Tender Offer Follow?

This article was originally published in PharmAsia News

Executive Summary

NEW DELHI - Alkaloida Chemical, an indirect subsidiary of Mumbai-based Sun Pharmaceutical, has bought a 9.4 percent stake in Taro Pharmaceutical from Brandes Investment Partners, taking Sun's holdings of the Israeli generic drug maker to 34.4 percent as it attempts to complete an acquisition that has stalled over the offer price

You may also be interested in...



India’s Sun Pharma To Pursue Taro Merger As Q4 Profits Surge On U.S. Protonix Sales

NEW DELHI - India's Sun Pharmaceutical said it is "on strong ground" to complete a merger with Taro Pharmaceutical at $10.25 a share, despite a rebuff by the Israel-based firm, as it reported higher than forecast earnings for the fourth quarter ended March 31 on strong sales of generic Protonix (pantoprazole) in the U.S

India’s Sun Pharma To Pursue Taro Merger As Q4 Profits Surge On U.S. Protonix Sales

NEW DELHI - India's Sun Pharmaceutical said it is "on strong ground" to complete a merger with Taro Pharmaceutical at $10.25 a share, despite a rebuff by the Israel-based firm, as it reported higher than forecast earnings for the fourth quarter ended March 31 on strong sales of generic Protonix (pantoprazole) in the U.S

Sun Pharmaceutical To Start Generic Protonix Sales in U.S.

NEW DELHI - India's Sun Pharmaceutical said it would immediately begin sales of a generic version of Wyeth's heartburn drug Protonix (pantoprazole) in the U.S., a move expected to be matched by Israel's Teva Laboratories for a market estimated at $2.3 billion

UsernamePublicRestriction

Register

GB150366

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel